ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer

Pfizer and Merck KGaA’s Bavencio is having itself an ASCO. In addition to putting up game-changing results in bladder cancer, it’s posted a win in a rare, chemo-resistant gynecological cancer, too.

In a small phase 2 study, the checkpoint inhibitor staved off a relapse in 8 of 15 women with gestational trophoblastic tumors that couldn’t be treated with single-agent chemo.